Source:http://linkedlifedata.com/resource/pubmed/id/10925067
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2000-8-24
|
pubmed:abstractText |
The effects of synthetic somatostatin analogue, octreotide, on fractional kidney weight (FKW), urinary protein excretion (UPE), creatinine clearance (Cl(cre)) and renal morphological changes were studied in alloxan-diabetic and non-diabetic rats comparatively. Diabetic rats were treated with twice daily s.c. injections of octreotide (2x2.5 microg) for 90 days. Untreated diabetic and non-diabetic animals were used as reference. The body weights and blood glucose levels of the animals were followed-up throughout the study period. After 90 days, FKW and renal morphology were evaluated. When compared to octreotide-treated diabetic group (O-D: 1.96+/-0. 23), normal control rats (NC: 1.24+/-0.05) showed a lower FKW (P<0. 05) and the FKW value of non-treated diabetic controls (DC: 2.74+/-0. 17) were significantly higher (P<0.05). Cl(cre) values were calculated at 45th and 90th days. At the 45th day, Cl(cre) values (ml/min) of O-D group (0.75+/-0.06) and NC group (0.56+/-0.09) were significantly lower than non-treated DC group (1.05+/-0.1) (P<0.05). However, at the 90th day no significant difference in Cl(cre) was observed. At the 45th day, UPE (mg/dl/day) was significantly higher in non-treated DC group (1000.45+/-392.38) when compared to NC group (236+/-36.59) (P<0.005) and UPE levels of O-D group were only slightly lower than that of non-treated diabetic group. At the 90th day, no significant beneficial effect of octreotide on UPE was observed. Octreotide did not prevent the histopathological changes related to diabetes. In conclusion, 5 microg/day octreotide administrations to diabetic rats for 90 days prevented renal weight increase but this treatment were insufficient to decrease the histopathological changes, UPE and increased Cl(cre).
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
1056-8727
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
14
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
53-9
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:10925067-Animals,
pubmed-meshheading:10925067-Blood Glucose,
pubmed-meshheading:10925067-Body Weight,
pubmed-meshheading:10925067-Capillaries,
pubmed-meshheading:10925067-Creatinine,
pubmed-meshheading:10925067-Diabetes Mellitus, Experimental,
pubmed-meshheading:10925067-Endothelium, Vascular,
pubmed-meshheading:10925067-Kidney,
pubmed-meshheading:10925067-Kidney Glomerulus,
pubmed-meshheading:10925067-Male,
pubmed-meshheading:10925067-Metabolic Clearance Rate,
pubmed-meshheading:10925067-Microscopy, Electron,
pubmed-meshheading:10925067-Octreotide,
pubmed-meshheading:10925067-Organ Size,
pubmed-meshheading:10925067-Proteinuria,
pubmed-meshheading:10925067-Rats,
pubmed-meshheading:10925067-Rats, Wistar
|
pubmed:articleTitle |
Octreotide administration in diabetic rats: effects on renal function and morphology.
|
pubmed:affiliation |
Department of Internal Medicine, Gülhane School of Medicine, Ankara, Turkey.
|
pubmed:publicationType |
Journal Article
|